Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
07 Dezembro 2023 - 6:05PM
Business Wire
Exelixis, Inc. (Nasdaq: EXEL) today announced that it will
webcast the Exelixis 2023 R&D Day: Science & Strategy event
taking place on Tuesday, December 12, 2023, from 9:00 a.m. to 12:30
p.m. EST. During the event, featured speakers will review the
progress of the company’s growing research and development
pipeline, highlight recent clinical updates and elaborate on the
company’s continued efforts to serve more patients with cancer and
generate sustainable, long-term value for shareholders.
The event will be livestreamed and can be accessed via
EXELRDDay.com. The registration access code is:
EXELScience&Strategy. The webcast of the event will also be
available at www.exelixis.com on the Event Calendar page under the
Investors & News heading for one year.
About Exelixis
Exelixis is a globally ambitious oncology company innovating
next-generation medicines and regimens at the forefront of cancer
care. Powered by bi-coastal centers of discovery and development
excellence, we are rapidly evolving our product portfolio to target
an expanding range of tumor types and indications with our
clinically differentiated pipeline of small molecules,
antibody-drug conjugates and other biotherapeutics. This
comprehensive approach harnesses decades of robust investment in
our science and partnerships to advance our investigational
programs and extend the impact of our flagship commercial product,
CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific
pursuit to create transformational treatments that give more
patients hope for the future. For information about the company and
its mission to help cancer patients recover stronger and live
longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter),
like Exelixis, Inc. on Facebook and follow Exelixis on
LinkedIn.
Exelixis, the Exelixis logo and CABOMETYX are
registered U.S. trademarks.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231207762237/en/
Investors Contact: Varant Shirvanian Associate Director,
Investor Relations Exelixis, Inc. 650-837-7917
vshirvanian@exelixis.com
Media Contact: Hal Mackins For Exelixis, Inc.
415-994-0040 hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Exelixis (NASDAQ:EXEL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024